Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Island Pharmaceuticals Ltd ( (AU:ILA) ) has provided an update.
Island Pharmaceuticals Ltd has lodged a request for a Type C meeting with the US FDA to discuss the development of its antiviral drug, Galidesivir, for treating Marburg virus. The company aims to utilize the FDA’s Animal Rule to fast-track Galidesivir’s approval, with plans to conduct an animal study next quarter. This strategic move aligns with Island’s goal to become a trusted provider for government stockpiles, addressing high-priority public health threats.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on addressing urgent viral diseases, public health, or biosecurity threats. The company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir, targeting diseases such as dengue fever and high-priority threats like Ebola, Marburg, and Zika.
Average Trading Volume: 646,147
Technical Sentiment Signal: Buy
Current Market Cap: A$55.49M
For detailed information about ILA stock, go to TipRanks’ Stock Analysis page.